Celldex Therapeutics reported $72.18M in Cash and Equivalent for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Amgen AMGN:US $ 11969M 5339M
Applied Genetic Technologies AGTC:US $ 90.52M 14.54M
Aptinyx Inc APTX:US $ 125.29M 3.94M
Arena Pharmaceuticals ARNA:US $ 386.65M 127.52M
Bristol Myers Squibb BMY:US $ 13540M 2516M
Celldex Therapeutics CLDX:US $ 72.18M 28.74M
Cytrx CYTR:US 16.46M 8.02M
Glaxosmithkline GSK:US $ 3453M 50M
Immunogen IMGN:US $ 245.76M 6.22M
Merrimack Pharmaceuticals MACK:US $ 14.04M 1.78M
Nektar Therapeutics NKTR:US $ 54.02M 98.33M
Newlink Genetics NLNK:US $ 100.65M 7.05M
Northwest Biotherapeutics NWBO:US 3.84M 78K
Rigel Pharmaceuticals RIGL:US $ 30.4M 54.42M
Seattle Genetics SGEN:US $ 685.17M 271.74M